Serum copper and zinc and the risk of death from cancer and cardiovascular disease
January 1988
Article
| Related Files |
|---|
|
(1890.pdf, 5.8MB) |
To investigate the association of serum copper and zinc with mortality from cancer and cardiovascular disease, the authors performed a case-control analysis of data obtained in a Dutch prospective follow-up study. Cancer (n = 64) and cardiovascular disease (n = 62) deaths and their matched controls were taken from a cohort of 10,532 persons examined in 1975-1978. Trace elements were measured in baseline serum samples, which had been stored during the six to nine years of follow-up. The adjusted risk of death from cancer and cardiovascular disease was about four times higher for subjects in the highest serum copper quintile (greater than 1.43 mg/liter) compared with those with normal levels. The excess mortality observed in subjects with low copper status suggests a U-shaped relation. No significant change in the risk of death from cancer and cardiovascular disease was found for subjects with low or high baseline levels of serum zinc. However, a protective effect of a high zinc status on the risk of cancer and cardiovascular disease is compatible with the data. For definitive conclusions, analysis of larger prospective data sets is recommended.
- Male
- Human
- Support, Non-U.S. Gov't
- Aged
- Female
- Follow-Up Studies
- Prospective Studies
- Risk Factors
- Middle Aged
- Netherlands
- 7440-66-6 (Zinc)
- Cancer
- 7440-50-8 (Copper)
- Cardiovascular Diseases/blood/*mortality
- Copper/*blood
- Neoplasms/blood/*mortality
- Zinc/*blood